Baidu
map

CEBP:女性喝咖啡可降低患子宫内膜癌的风险

2015-02-11 毛梦莹 谭利娅 环球网

据“世界科学报告”网站(scienceworldreport)2月8日报道,之前的研究都夸大了喝咖啡的好处。现在,最近发布在《癌症流行病学生物标记和预防》杂志上的发现揭示了喝四杯或更多的含咖啡因饮料能帮助女性降低高达18%的患子宫内膜癌的风险。 在这项研究中,研究者们评估了超过2800个有健康问题的女性的饮食习惯。他们发现,每天喝超过4杯咖啡的女性比不喝咖啡或是喝较少咖啡的女性的患子宫内膜癌的风

子宫内膜癌如何治疗?八大治疗方法介绍

最近发布在《癌症流行病学生物标记和预防》杂志上的发现揭示了喝四杯或更多的含咖啡因饮料能帮助女性降低高达18%的患子宫内膜癌风险

在这项研究中,研究者们评估了超过2800个有健康问题的女性的饮食习惯。他们发现,每天喝超过4杯咖啡的女性比不喝咖啡或是喝较少咖啡的女性的患子宫内膜癌的风险减少了18%。

数据显示,今年估计有5.5万女性可能患有子宫内膜癌,而在较严重的案例中,这个病是致命的。这些发现是基于之前的研究,而那些研究表明咖啡可能能够降低健康问题的风险。

伦敦帝国理工学院癌症流行病的研究成员,以及此次研究的领导者梅丽莎·梅里特在最近的新闻中透露:“摄入咖啡量的不同跟降低子宫内膜癌的风险是有关的。我们并没有对此感到惊讶, 因为这与之前的研究中的结论是一致的。”她还说,“我们使用与之前研究类似的方法来调查咖啡摄入量与子宫内膜癌之间的联系。这很重要,因为我们可以将不同的研究的结果进行对比。”

然而,研究者们注意到咖啡和降低的子宫内膜癌之间的联系并一定是因果关系。而且这项研究并没有区分常规咖啡和无咖啡因咖啡。事实上,一些研究甚至表示喝咖啡会引发健康问题。例如,一些情况下,过量的咖啡因与多动症,失眠甚至是抑郁有关。

报道说,尽管没有明确的原因会导致子宫内膜癌,研究人员认识到一些特定的风险,包括荷尔蒙失调,糖尿病以及肥胖,会增加健康问题的可能性。健康的饮食以及锻炼能帮助降低健康问题的风险。

MedSci进一步检索了相关文献,在2014年另一项瑞士研究,在1991-1992年招募了42270位30-49岁中年女性进行研究( Swedish Women's Lifestyle and Health cohort),直至2009年随访结束。最终有144位患者患有子宫内膜癌。结果显示,不管有没有患子宫内膜癌的女性,使用咖啡(405 vs. 406 mg),茶叶 (104 vs. 115 g),和咖啡因摄入 (405 vs. 406 mg)都是相似的。每天使用2杯以下咖啡人群和3杯以上人群进行对比,其相对风险为1.56(95% CI: 0.94-2.59; P for trend = 0.17),即便按四分位数,比较最低与最高咖啡使用人群之比,也没有看到差异。至少这个研究没有发现咖啡与子宫内膜癌之间的联系。

但是同期挪威一项研究结果相反,这项研究共纳入97926名绝经后女性(NOWAC研究),通过10.9年的随访,共有462名女性患上子宫内膜癌。进行多因素分析发现,每天8杯咖啡以上人群患子宫内膜癌风险显著下降,为0.52 (95% CI 0.34-0.79)。然而并没有看到显著的剂量依赖性作用。这项研究似乎表明,每天大量使用咖啡,能看到一定的保护效应

原始出处:

Merritt MA, Tzoulaki I, Tworoger SS, De Vivo I, Hankinson SE, Fernandes J, Tsilidis KK, Weiderpass E, Tjønneland A, Petersen KE, Dahm CC, Overvad K, Dossus L, Boutron-Ruault MC, Fagherazzi G, Fortner RT, Kaaks R, Aleksandrova K, Boeing H, Trichopoulou A, Bamia C, Trichopoulos D, Palli D, Grioni S, Tumino R, Sacerdote C, Mattiello A, Bueno-de-Mesquita HB, Onland-Moret NC, Peeters PH, Gram IT, Skeie G, Quirós JR, Duell EJ, Sánchez MJ, Salmerón D, Barricarte A, Chamosa S, Ericson U, Sonestedt E, Nilsson LM, Idahl A, Khaw KT, Wareham N, Travis RC, Rinaldi S, Romieu I, Patel CJ, Riboli E, Gunter MJ.Investigation of Dietary Factors and Endometrial Cancer Risk Using a Nutrient-wide Association Study Approach in the EPIC and Nurses' Health Study (NHS) and NHSII.Cancer Epidemiol Biomarkers Prev. 2015 Feb;24(2):466-71

Weiderpass E, Sandin S, Lof M, Oh JK, Inoue M, Shimazu T, Tsugane S, Adami HO.Endometrial cancer in relation to coffee, tea, and caffeine consumption: a prospective cohort study among middle-aged women in Sweden.Nutr Cancer. 2014;66(7):1132-43

Gavrilyuk O, Braaten T, Skeie G, Weiderpass E, Dumeaux V, Lund E.High coffee consumption and different brewing methods in relation to postmenopausal endometrial cancer risk in the Norwegian women and cancer study: a population-based prospective study.BMC Womens Health. 2014 Mar 25;14:48.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708311, encodeId=69a51e08311f8, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Wed Apr 15 03:52:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23660, encodeId=2ab52366021, content=非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:11:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22920, encodeId=c09e2292080, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu May 07 22:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16016, encodeId=d86f160168d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:26:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15753, encodeId=4cf915e5351, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:59:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15355, encodeId=780b1535524, content=MedSci评论上看,应该还没有定论, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.233.**, createdTime=Wed Feb 11 23:54:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708311, encodeId=69a51e08311f8, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Wed Apr 15 03:52:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23660, encodeId=2ab52366021, content=非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:11:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22920, encodeId=c09e2292080, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu May 07 22:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16016, encodeId=d86f160168d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:26:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15753, encodeId=4cf915e5351, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:59:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15355, encodeId=780b1535524, content=MedSci评论上看,应该还没有定论, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.233.**, createdTime=Wed Feb 11 23:54:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-05-16 ljjj1053

    非常好的文章

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1708311, encodeId=69a51e08311f8, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Wed Apr 15 03:52:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23660, encodeId=2ab52366021, content=非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:11:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22920, encodeId=c09e2292080, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu May 07 22:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16016, encodeId=d86f160168d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:26:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15753, encodeId=4cf915e5351, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:59:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15355, encodeId=780b1535524, content=MedSci评论上看,应该还没有定论, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.233.**, createdTime=Wed Feb 11 23:54:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-05-07 zhouanxiu

    实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1708311, encodeId=69a51e08311f8, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Wed Apr 15 03:52:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23660, encodeId=2ab52366021, content=非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:11:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22920, encodeId=c09e2292080, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu May 07 22:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16016, encodeId=d86f160168d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:26:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15753, encodeId=4cf915e5351, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:59:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15355, encodeId=780b1535524, content=MedSci评论上看,应该还没有定论, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.233.**, createdTime=Wed Feb 11 23:54:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-02-16 Johnny1989

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1708311, encodeId=69a51e08311f8, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Wed Apr 15 03:52:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23660, encodeId=2ab52366021, content=非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:11:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22920, encodeId=c09e2292080, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu May 07 22:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16016, encodeId=d86f160168d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:26:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15753, encodeId=4cf915e5351, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:59:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15355, encodeId=780b1535524, content=MedSci评论上看,应该还没有定论, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.233.**, createdTime=Wed Feb 11 23:54:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    以阅

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1708311, encodeId=69a51e08311f8, content=<a href='/topic/show?id=4c2d3051535' target=_blank style='color:#2F92EE;'>#内膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30515, encryptionId=4c2d3051535, topicName=内膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=730431558473, createdName=12498974m61暂无昵称, createdTime=Wed Apr 15 03:52:00 CST 2015, time=2015-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23660, encodeId=2ab52366021, content=非常好的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=154, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:11:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=22920, encodeId=c09e2292080, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu May 07 22:36:00 CST 2015, time=2015-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16016, encodeId=d86f160168d, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cce01615276, createdName=Johnny1989, createdTime=Mon Feb 16 15:26:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15753, encodeId=4cf915e5351, content=以阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 13:59:00 CST 2015, time=2015-02-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15355, encodeId=780b1535524, content=MedSci评论上看,应该还没有定论, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.0.233.**, createdTime=Wed Feb 11 23:54:00 CST 2015, time=2015-02-11, status=1, ipAttribution=)]
    2015-02-11 175.0.233.**

    MedSci评论上看,应该还没有定论

    0

相关资讯

ASTRO循证指南:术后放射治疗在子宫内膜癌中的应用

美国放射肿瘤学会(ASTRO)颁布了一项关于子宫内膜癌辅助放疗使用细节的新指南。专家组针对上述患者人群给出了一系列关于子宫切除术后补充放疗、阴道断端放疗、术后外照射放疗、近距离放疗以及外照射放疗、和化放疗等的推荐意见。该指南名为“术后放射治疗在子宫内膜癌中的应用:ASTRO循证指南”。该指南的摘要发表在Practical Radiation Oncology 杂志2014年5-7月版。ASTRO

Cancer:二磷酸盐可降低子宫内膜癌风险

子宫内膜癌常见于60-70岁骨密度降低的绝经后女性。在女性最常见癌症中排名第四,在癌症最常见死亡原因中排名第八。近一半的妇科癌症是子宫内膜癌。之前的研究表明二磷酸盐可以减缓某些类型癌症患者的肿瘤细胞生长速度,但是没有专门有关子宫内膜癌的研究。 12月22日,亨利福特医院公共健康学部门的奥尔福德博士和他的同事在《癌症》杂志上发表的一项最新研究表明,防止骨质流失的药物还能有助于降低女性患子宫

Cancer:骨质疏松症治疗药物有助预防子宫内膜癌

一项新的分析表明,使用双磷酸盐类药物(此类药物通常用于治疗骨质疏松症和其他骨疾病)的女性发展子宫内膜癌的风险是不使用此类药物妇女患子宫内膜癌风险的一半左右。此项研究发表于Cancer杂志上,研究表明这种类型的药物有一定抗癌作用。在美国,近50%的妇科癌症为子宫内膜癌,而且它是第四个最常见的恶性肿瘤,是癌症死亡的第八最常见原因。双膦酸盐是已知的能防止骨损失的药物,临床前研究表明,该药物也具有抗肿瘤作

PLoS Medicine:子宫内膜癌可能与HAND2甲基化有关

来自英国伦敦大学学院妇女癌症部的研究人员在11月12日的PLOS Medicine杂志上发表了一项最新研究:发现HAND2基因是子宫内膜癌中的一种差异甲基化热点,这个基因的表观遗传学修饰在子宫内膜癌的发展中起着关键的作用。 作为一种能够引起全球13%死亡人数的疾病,癌症能够在人体的任何地方发生,但是所有癌症都有这样的特征:不受控制的细胞生长和细胞分化减少。遗传改变——在特定基因中的核苷酸序列的变

含糖饮料或增子宫内膜癌风险

研究者们发现,喝越多含糖饮料的女子,患雌激素依赖型子宫内膜癌的风险越高。相比不喝饮料的妇女们,那些一周喝掉60瓶富含糖份饮料的女子会增加78%的患癌症风险。 癌症流行病学日报的生物指标及预防栏目, 这个结果基于研究人员考虑了其他能影响癌症风险的因素,比如运动、糖尿病、吸烟和体质指数。 研究人员说:“调查结果表明,忽略其他生活方式因素,喝含糖饮料可能是患子宫内膜癌(Ⅰ型)的风险因素。” 据美国国

Obstet Gynecol:他莫昔芬和子宫内膜癌

他莫昔芬是一种非类固醇抗雌激素药物,被广泛用于乳腺癌的辅助治疗。美国FDA推荐的他莫昔芬的适应症为: ●乳腺癌辅助治疗; ●转移性乳腺癌治疗; ●具有乳腺癌高危因素的妇女预防性应用以降低乳腺癌的发病率。 因为妇产科医师经常治疗患乳腺癌和有乳腺癌高危因素的妇女,在诊疗过程中她们可能会被咨询到关于使用他莫昔芬妇女合适的随诊建议。该委员会的意见为总结风险并推荐治疗方案来预

Baidu
map
Baidu
map
Baidu
map